查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1714734

药物安全检测市场按类型、产品生命週期、交付模式、流程、治疗领域和最终用户划分－2025 年至 2030 年全球预测

Pharmacovigilance Market by Type, Product Life Cycle, Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计药物安全检测市场规模到 2024 年将达到 102.4 亿美元，到 2025 年将达到 118.4 亿美元，到 2030 年将达到 247.6 亿美元，复合年增长率为 15.85%。

主要市场统计数据
基准年2024年 102.4亿美元
预计2025年 118.4亿美元
预测年份 2030 247.6亿美元
复合年增长率（%） 15.85%

在当今快速发展的医疗保健环境中，药物安全检测在确保病人安全和维护临床研究方法的完整性方面发挥着至关重要的作用。随着药物和治疗性介入变得越来越复杂，监测、分析和减轻副作用的需求也越来越强烈。该行业正处于一个十字路口，传统实践正在被资料主导的洞察力和技术创新所改变。这份全面的执行摘要透过详细研究创新流程、市场区隔、区域动态和推动产业转型的主要企业，探索了药物安全检测的多方面格局。透过建立严谨的科学方法并利用先进的数位工具，相关人员不仅可以提高安全监测的有效性，还可以创建在问题影响公众健康之前预测问题的主动系统。

本书为专家和决策者提供了丰富、分析性且易于理解的概述。深入分析和可操作见解的结合清晰地描绘了药物安全检测的现状，并强调了新兴趋势如何重新定义业务模式和合规标准。随着该领域不断整合更全面的资料来源并采用创新技术，未来有望提高灵活性和精确度，从而显着改善治疗监测和整个药物开发生命週期。

引言首先承认了药物安全检测的复杂性，并强调了严格的资料分析、加强监管合规性和跨部门合作的迫切需求。它强调了结合传统方法和现代数位解决方案的重要性，以确保不仅记录不利事件，而且还对其进行解释以采取预防措施。本质上，本节为深入探讨当代药物安全检测市场的变革性变化和策略见解奠定了基础。

重新定义药物安全检测格局的转型

在过去的十年中，药物安全检测领域经历了一系列变革，改变了安全资料的收集、分析和处理方式。数位科技与即时资料分析的整合正在开启一个新时代，传统的被动不利事件报告模式正被主动和预测性的方法所取代。

最大的转变之一是从手动、纸本报告系统转向全自动、资料主导的解决方案。先进的演算法和机器学习技术越来越多地被用来筛选来自各种资讯来源的大量非结构化资料。这不仅加速了潜在安全讯号的识别，而且提高了调查结果的准确性和可靠性。

另一个转变是法律规范和合规标准的演变。世界各地的监管机构正在更新其指导方针，以跟上资料分析快速创新的步伐。这种不断变化的情况迫使製药和生物技术公司重新调整其内部流程，以满足新法规所要求的更高的透明度和课责标准。

医疗保健和技术的融合也促进了相关人员之间的更大合作。公营和私营部门正在联手建立更强大的药物安全检测系统。采用即时电子健康记录(EHR) 挖掘和增强药物不良反应 (ADR) 报告方法对于及早发现新出现的安全问题至关重要。此外，对有针对性的自愿报告的日益重视为更有针对性和更有效的资料分析铺平了道路，这可以直接有利于患者安全。

随着组织不断投资数位基础设施并开发更复杂的风险管理系统，手动流程带来的传统限制正在迅速消失。这一变革时期将以转向更整合、自动化和预测性的模型为标誌，这些模型不仅可以简化业务，还可以大大降低出错的可能性。摘要，由于技术进步、监管标准的更新以及更协调的全球药物安全方法，药物安全检测领域正在发生重大转变。

洞察推动市场动态的关键细分领域

深入研究市场可以发现，细分可以为药物安全检测业务的多面性提供宝贵的清晰度。整体方法主要透过不同的业务和分析方法以及药物开发的各个阶段进行细分，它们共同构成了不断发展的行业的综合视图。

基于类型的分析将市场分为群组心臟事件记录器、电子健康记录(EHR) 挖掘、增强药物不良反应 (ADR) 报告、自发性报告和有针对性的自发性报告等群组。每种方法都是获取安全资料的独特方式，数位工具的不断发展为行业专业人士提供了更深层的报告和分析。

深入研究产品生命週期可以发现临床阶段的结构化进展，包括第一阶段、第二阶段、第三阶段、第四阶段和临床前阶段。这个细分强调了药物安全检测如何与药物开发的每个阶段紧密结合，确保从早期检测到上市后监测的安全评估至关重要。此序列不仅确保遵守监管义务，而且还建立了可以推动未来研究和药物开发策略的纵向安全资料。

当考虑到交付模式时，业务服务和委託服务之间就会出现明显的差异。为了优化风险管理系统，公司越来越多地寻求外部专业知识，特别是在专业知识至关重要的领域。内部和外包模式都有各自的优势，而选择将在很大程度上受到组织的内部能力、预算考量和策略重点的影响。

流程细分提供了关键操作元件的全面视图，包括案例资料管理、风险管理系统和讯号侦测。在病例资料管理中，病例资料分析、病例记录、医疗审查和彙报等方面都受到严格审查，以确保准确记录和分析每个不利事件。同样，风险管理系统进一步细分为风险评估系统和风险缓解系统等组成部分，强调如何不仅评估风险，而且还主动应对风险。此外，讯号检测整合了多层分析，包括不利事件分析、不利事件记录以及不利事件审查和报告。这种多层次的方法确保了一种强大的机制，透过该机制可以严格评估所有潜在的安全讯号，从而实现快速的决策流程。

就治疗领域而言，市场主要关注心血管疾病、感染疾病、神经学、肿瘤学和呼吸系统疾病。这种细分反映了药物安全检测对不同疾病状况的不同影响，每种疾病都有其独特的安全性和报告细微差别。例如，在肿瘤学中，治疗的复杂交互作用和潜在不利事件的严重性需要提高警惕，而在神经病学中，重点可能放在与对中枢神经系统的影响相关的多重挑战。

最后，根据最终用户细分包括生技公司、医疗设备製造商和製药公司。这种分类不仅强调了药物安全检测原则在医疗保健市场不同领域的广泛应用，而且强调了需要根据每个领域的具体需求和业务规模来制定报告框架。每个最终用户群体都带来不同的要求和挑战，这推动了创新和更细緻的安全监控通讯协定的开发。

总的来说，这些细分见解提供了药物安全检测市场的详细视图。这些见解表明，一系列业务、发展和地理因素相互交织，形成了一个不断适应新挑战和机会的动态系统。这种深入的分析可以作为了解市场趋势的蓝图，并确定在快速变化的环境中推动竞争优势的策略重点。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全面药物警戒和上市后监测的监管要求不断提高
      • 人工智慧、机器学习和巨量资料分析的进步改善了不利事件侦测
      • 全球药品不良反应发生率的不断上升以及公众意识的不断增强推动了药物安全检测服务的需求。
    • 限制因素
      • 实施强大的药物安全检测系统需要高昂的营运成本和资源彙整
    • 机会
      • 亚太和拉丁美洲的新兴市场为医疗保健投资提供了成长机会
      • 云端基础的即时安全监控解决方案在加强药物安全检测流程的潜力
    • 任务
      • 难以整合不同的资料来源并确保跨全球系统的互通性
  • 市场区隔分析
    • 类型：越来越多地采用 EHR 挖掘来分析患者资料，以识别潜在的 ADR
    • 最终用户：医疗设备製造商越来越多地应用药物安全检测来有效地收集安全资料和不利事件报告。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章药物安全检测市场（按类型）

  • 群组心臟事件记录器
  • EHR挖掘
  • 增强型 ADR 报告
  • 自发性报告
  • 有针对性和自发性的报道

第七章药物安全检测市场（依产品生命週期）

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段
  • 临床前

第 8 章药物安全检测市场（以交付方式）

  • 内部
  • 外包

第九章药物安全检测市场（依流程）

  • 病例资料管理
    • 案例资料分析
    • 案例日誌
    • 医疗审查和报告
  • 风险管理系统
    • 风险评估系统
    • 风险缓解系统
  • 讯号检测
    • 不利事件分析
    • 记录不利事件
    • 不利事件审查和报告

第 10 章药物安全检测市场（依治疗领域）

  • 心血管系统
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 呼吸系统

第 11 章药物安全检测市场（依最终使用者）

  • 生技公司
  • 医疗设备製造商
  • 製药

第 12 章：美洲药物安全检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太药物安全检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲药物安全检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi SA
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited
Product Code: MRR-43676CF420A3

The Pharmacovigilance Market was valued at USD 10.24 billion in 2024 and is projected to grow to USD 11.84 billion in 2025, with a CAGR of 15.85%, reaching USD 24.76 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 10.24 billion
Estimated Year [2025] USD 11.84 billion
Forecast Year [2030] USD 24.76 billion
CAGR (%) 15.85%

In today's rapidly evolving healthcare environment, pharmacovigilance plays a critical role in ensuring patient safety and maintaining the integrity of the clinical research process. As medicines and therapeutic interventions become increasingly sophisticated, the need to monitor, analyze, and mitigate adverse drug reactions has never been more paramount. The industry stands at a crossroads where traditional practices are being revolutionized by data-driven insights and technological innovation. This comprehensive executive summary explores the multifaceted landscape of pharmacovigilance through detailed examination of innovative processes, market segmentation, regional dynamics, and key players driving industry transformation. By building on a foundation of rigorous scientific methodology and leveraging advanced digital tools, stakeholders can not only enhance the efficacy of safety monitoring but also build a proactive system that anticipates issues before they impact public health.

This document presents a rich overview that is both analytical and accessible, catering to experts and decision-makers alike. Through a blend of detailed analysis and actionable insights, the discussion offers a clear view of the current state of pharmacovigilance, highlighting how emerging trends are redefining operational models and compliance standards. As the field continues to integrate more comprehensive data sources and adopt innovative technologies, the future landscape promises to be one where increased agility and precision lead to significant improvements in therapeutic monitoring and the overall drug development lifecycle.

The introduction sets the stage by acknowledging the complexity of pharmacovigilance and emphasizing the urgent need for meticulous data analysis, enhanced regulatory compliance, and cross-functional collaborations. It underscores the importance of embracing both traditional methods and modern digital solutions to ensure that adverse events are not only recorded but are also interpreted for preventive action. In essence, this section forms the basis for a deep dive into the transformative shifts and strategic insights that underpin the contemporary pharmacovigilance market.

Transformative Shifts Redefining the Pharmacovigilance Landscape

Over the past decade, the field of pharmacovigilance has witnessed a series of transformative shifts that are reshaping the way safety data is collected, analyzed, and acted upon. The integration of digital technologies and real-time data analytics has ushered in a new era where the traditional reactive models of adverse event reporting are being replaced by proactive and predictive approaches.

One of the most significant shifts has been the transition from paper-based and manual reporting systems to fully automated, data-driven solutions. Advanced algorithms and machine learning techniques are increasingly being employed to sift through massive volumes of unstructured data obtained from various sources. This not only accelerates the identification of potential safety signals but also enhances the accuracy and reliability of the findings.

Another transformative change involves the evolution of regulatory frameworks and compliance standards. Regulatory bodies across the globe are updating their guidelines to accommodate the rapid pace of innovation in data analytics. This evolving landscape has compelled pharmaceutical and biotechnology companies to recalibrate their internal processes, aligning them with the higher standards of transparency and accountability that these new regulations demand.

The convergence of healthcare and technology has also led to enhanced collaboration among stakeholders. Public and private sectors are joining forces to create more robust pharmacovigilance systems. The adoption of real-time electronic health record (EHR) mining and intensified adverse drug reaction (ADR) reporting methods has been pivotal in catching emerging safety issues early on. Furthermore, the growing emphasis on targeted spontaneous reporting has opened up avenues for more focused and efficient data analysis that directly benefits patient safety.

As organizations continue to invest in digital infrastructure and develop more sophisticated risk management systems, the traditional limitations imposed by manual processes are quickly becoming obsolete. This transformative period is characterized by a shift towards a more integrated, automated, and predictive model that not only streamlines operations but also significantly reduces the margin of error. In summary, the pharmacovigilance landscape is undergoing a profound metamorphosis driven by technological advancements, updated regulatory standards, and a more harmonized global approach to drug safety.

Key Segmentation Insights Driving Market Dynamics

A deep dive into the market reveals that segmentation offers valuable clarity into the multifaceted nature of pharmacovigilance operations. The overall approach is segmented primarily by different operational and analytic methodologies as well as by the various stages of drug development, which together form a composite view of the evolving industry.

An analysis based on type categorizes the market into cohorts such as Cohort Event Monitoring, Electronic Health Record (EHR) Mining, Intensified Adverse Drug Reaction (ADR) Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting. Each of these methods represents a unique approach to capturing safety data, with the continuous evolution of digital tools further enhancing the depth of reporting and analysis available to industry professionals.

Delving into the product life cycle reveals a structured progression through clinical phases including Phase I, Phase II, Phase III, Phase IV, and the Pre-clinical stage. This segmentation highlights how pharmacovigilance is intricately woven into every stage of drug development, ensuring that safety evaluations are integral from early discovery through to post-marketing surveillance. This continuum not only ensures compliance with regulatory mandates but also builds a repository of longitudinal safety data that can drive future research and drug development strategies.

Examining delivery mode brings to light the clear distinction between in-house operations and outsourced services. Companies are increasingly leveraging external expertise to optimize their risk management systems, particularly in the areas where specialized knowledge is critical. Both in-house and outsourced models have unique benefits, with the choice largely influenced by the organization's internal capabilities, budgetary considerations, and strategic focus.

The process flow segmentation provides a comprehensive look at critical operational components, which include Case Data Management, Risk Management System, and Signal Detection. Within Case Data Management, facets such as Case Data Analysis, Case Logging, and Medical Reviewing & Reporting are meticulously scrutinized to ensure that each adverse event is documented and analyzed with precision. Similarly, the Risk Management System is further dissected into components such as Risk Evaluation System and Risk Mitigation System, emphasizing how risk is not only assessed but also proactively addressed. Further along the process, Signal Detection integrates multiple layers of analysis including Adverse Event Analysis, Adverse Event Logging, and Adverse Event Review & Reporting. This layered approach ensures a robust mechanism where every potential safety signal is critically evaluated, enabling rapid decision-making processes.

From the perspective of therapeutic areas, the market is stratified to focus on conditions spanning Cardiovascular diseases, Infectious Diseases, Neurology, Oncology, and Respiratory disorders. This segmentation reflects the varied impacts that pharmacovigilance has across different medical conditions, each with its specific safety profiles and reporting nuances. For example, oncology calls for heightened vigilance owing to the complex interplay of treatments and the severity of potential adverse events, whereas neurology might focus on different sets of challenges tied to central nervous system effects.

Lastly, the segmentation based on end-user encompasses Biotechnology Companies, Medical Device Manufacturers, and Pharmaceuticals. Such a categorization not only reveals the broad application of pharmacovigilance principles across different segments of the healthcare market but also underscores the need for tailored reporting frameworks that align with the specific needs and operational scales of each segment. Each end-user group brings distinct requirements and challenges, which in turn drive innovation and the development of more nuanced safety monitoring protocols.

Overall, these segmentation insights provide a granular view of the pharmacovigilance market. They illustrate how different operational, developmental, and regional factors intertwine to create a dynamic system that is ever-adaptive to emerging challenges and opportunities. This detailed analysis serves as a blueprint for understanding market trends and identifies strategic focal points that can drive competitive advantage in a rapidly changing environment.

Based on Type, market is studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting.

Based on Product Life Cycle, market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical.

Based on Delivery Mode, market is studied across In-house and Outsourced.

Based on Process Flow, market is studied across Case Data Management, Risk Management System, and Signal Detection. The Case Data Management is further studied across Case Data Analysis, Case Logging, and Medical Reviewing & Reporting. The Risk Management System is further studied across Risk Evaluation System and Risk Mitigation System. The Signal Detection is further studied across Adverse Event Analysis, Adverse Event Logging, and Adverse Event Review & Reporting.

Based on Therapeutic Area, market is studied across Cardiovascular, Infectious Diseases, Neurology, Oncology, and Respiratory.

Based on End-user, market is studied across Biotechnology Companies, Medical Device Manufacturers, and Pharmaceuticals.

Key Regional Insights Illustrating Global Market Dynamics

When analyzing the market from a global perspective, regional dynamics play a crucial role in shaping the pharmacovigilance landscape. In the Americas, robust regulatory frameworks combined with significant investment in digital infrastructure have laid the foundation for advanced safety monitoring practices. These factors, along with strategic public-private partnerships, have accelerated the adoption of sophisticated pharmacovigilance technologies, setting a high standard for safety and compliance.

In the region encompassing Europe, Middle East & Africa, a diverse regulatory environment presents both challenges and opportunities. This patchwork of legislative mandates necessitates adaptive strategies that can cater to multiple standards while maintaining a consistent approach to safety reporting. The region benefits from a blend of mature markets in Europe and emerging scenarios in parts of the Middle East and Africa, which drives innovation through the exchange of best practices and convergent technological solutions.

Asia-Pacific is rapidly emerging as a significant hub of pharmacovigilance activity, largely driven by burgeoning pharmaceutical markets and an increasing focus on healthcare innovation. Here, dynamic economic growth coupled with investments in emerging digital technologies is significantly enhancing real-time data capture and analysis capabilities. The diversity of healthcare systems in this region offers a unique laboratory for implementing and refining novel pharmacovigilance models that can later be adapted to other markets.

These regional insights reveal not only the geographic disparities in technological adoption and regulatory enforcement but also emphasize the importance of localized strategies that can address unique market needs. The interplay between established markets and emerging economies provides a rich landscape for benchmarking best practices and fostering cross-regional innovation. Overall, each regional cluster contributes distinct perspectives and challenges to the global pharmacovigilance framework, enriching the overall market dynamics with its own set of robust, actionable insights.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Steering Industry Innovation

A multitude of industry-leading companies has cemented their position as pioneers in the realm of pharmacovigilance, driving both technological and methodological innovations. Organizations such as Accenture, PLC, and Bristol-Myers Squibb Company have been instrumental in setting new benchmarks for data integration and real-time monitoring. These enterprises, along with Capgemini SE and ClinChoice, have championed the use of advanced analytics to streamline the process of adverse event reporting.

Furthermore, industry giants like F. Hoffmann-La Roche AG and GlaxoSmithKline PLC have not only invested heavily in digital transformation but have also consistently demonstrated the value of a rigorous, systems-based approach to patient safety. HCL Technologies Limited, ICON PLC, and Infosys Limited add to this dynamic landscape through their respective innovations in digital infrastructure, cloud-based solutions, and bespoke software applications tailored for risk management.

International Business Machines Corporation and IQVIA Inc. have also been pivotal figures in forging a path toward more integrated and predictive pharmacovigilance systems. These companies, in conjunction with ITclinical and Laboratory Corporation of America Holdings, continue to push the envelope by leveraging big data and sophisticated statistical models for enhanced signal detection.

Linical Co., Ltd., Novartis AG, and Oracle Corporation further enrich this competitive space by delivering comprehensive solutions that integrate clinical data with advanced analytics. Their efforts have reinforced the importance of a seamless, end-to-end system that can capture the lifecycle of adverse events from initial logging to in-depth review and reporting. Parexel International, Pfizer Inc., and Quanticate International limited have also made significant contributions, particularly in the realm of harmonizing regulatory compliance with cutting-edge technological deployment.

The contributions of Sanofi S.A., Syneos Health, TAKE Solutions Limited, TATA Consultancy Services Limited, and Wipro Limited further illustrate the industry's collective drive towards innovation. These companies not only emphasize the integration of automation and digital transformation within their processes but also actively promote collaborative partnerships that bolster the overall safety ecosystem. Together, these industry leaders form a robust network that is redefining pharmacovigilance, making it more efficient, predictive, and ultimately patient-centric.

The report delves into recent significant developments in the Pharmacovigilance Market, highlighting leading vendors and their innovative profiles. These include Accenture, PLC, Bristol-Myers Squibb Company, Capgemini SE, ClinChoice, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, HCL Technologies Limited, ICON PLC, Infosys Limited, International Business Machines Corporation, IQVIA Inc., ITclinical, Laboratory Corporation of America Holdings, Linical Co., Ltd., Novartis AG, Oracle Corporation, Parexel International, Pfizer Inc., Quanticate International limited, Sanofi S.A., Syneos Health, TAKE Solutions Limited, TATA Consultancy Services Limited, and Wipro Limited. Actionable Recommendations for Forward-Thinking Industry Leaders

In the current state of pharmacovigilance, industry leaders must focus on a mix of strategic initiatives that not only adhere to regulatory standards but also leverage the power of technology and data analytics. First, there is a pressing need to invest in advanced digital infrastructure, which can support real-time data capture and facilitate more rapid and accurate signal detection. Companies should prioritize technologies that offer integrated solutions for case data management, risk evaluation, and mitigation strategies.

Secondly, fostering cross-functional and cross-industry collaboration is essential. Breaking down silos between departments such as clinical research, regulatory affairs, and IT can lead to a more unified approach to safety management. Such collaboration is instrumental in developing best practices and ensuring that insights gleaned from adverse event data are immediately incorporated into actionable strategies.

The development of robust, data-driven risk management systems should also be at the forefront of strategic initiatives. It is imperative to adopt solutions that not only streamline existing processes but also provide predictive analytics capable of identifying potential safety issues before they escalate. This includes ensuring comprehensive training for staff at all levels so that they are well-versed in both the technical and regulatory aspects of the enhanced systems.

Additionally, aligning internal processes with evolving global regulatory requirements is crucial. As regulatory bodies continue to refine safety protocols, companies must remain agile, updating their compliance frameworks to reflect the latest standards. This agility is not only critical for maintaining market trust but also for avoiding potential regulatory bottlenecks that could disrupt operations.

Finally, industry leaders should consider strategic partnerships with specialized firms that offer expertise in advanced data analytics and digital transformation. These collaborations can bridge knowledge gaps and provide the necessary technological edge, thereby positioning organizations to capitalize on emerging opportunities. In essence, a targeted approach that combines investment in technology, interdepartmental coordination, agile regulatory adherence, and strategic external partnerships will empower industry leaders to navigate the complexities of modern pharmacovigilance with confidence.

Conclusion Summarizing Critical Insights and Future Directions

The comprehensive analysis provided in this report underscores the multifaceted nature of pharmacovigilance and its critical role in ensuring drug safety and efficacy. Throughout the discussion, we have explored the transformative shifts in the industry, driven by digital innovation and evolving regulatory landscapes. The deep dive into market segmentation has illuminated the diverse methodologies and processes that underpin the pharmacovigilance framework, from the early detection of adverse events to the nuanced analysis performed across various stages of the product life cycle.

Regional insights reveal a global market where disparate regulatory environments and economic conditions create a mosaic of challenges and opportunities. Whether in the technologically advanced markets of the Americas, the diverse environments of Europe, Middle East & Africa, or the rapidly evolving Asia-Pacific region, the underlying principles of safety and compliance remain constant. These nuances highlight the necessity for tailored strategies that can address local market needs while also supporting global objectives.

Significantly, the role of key industry players cannot be overstated. The detailed overview of leading companies demonstrates the power of innovation and collaboration in boosting operational efficiencies and ensuring that pharmacovigilance systems remain robust and responsive. Their relentless pursuit of excellence through digital transformation, advanced analytics, and comprehensive risk management systems serves as a benchmark for the industry at large.

In conclusion, the insights presented here provide a clear roadmap for navigating the complexities of the pharmacovigilance landscape. They serve as both a reflection on current practices and a strategic guide for tapping into future opportunities. As the sector continues to adapt to rapid technological and regulatory changes, stakeholders who embrace these insights will be well-positioned to lead the charge in driving forward a new era of proactive and precision-based drug safety.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing regulatory requirements for comprehensive drug safety monitoring and post-market surveillance
      • 5.1.1.2. Advancements in AI, machine learning, and big data analytics driving improved adverse event detection
      • 5.1.1.3. Rising global incidence of ADRs and growing public awareness fueling demand for pharmacovigilance services
    • 5.1.2. Restraints
      • 5.1.2.1. High operational costs and resource-intensive nature of implementing robust pharmacovigilance systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging markets in Asia-Pacific and Latin America offering growth opportunities due to healthcare investments
      • 5.1.3.2. Potential for cloud-based real-time safety monitoring solutions enhancing pharmacovigilance processes
    • 5.1.4. Challenges
      • 5.1.4.1. Difficulty in integrating diverse data sources and ensuring interoperability across global systems
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of EHR mining to identify potential ADRs by analyzing patient data
    • 5.2.2. End-user: Rising application of pharmacovigilance in medical device manufacturers to efficiently capture safety data and adverse event reports
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmacovigilance Market, by Type

  • 6.1. Introduction
  • 6.2. Cohort Event Monitoring
  • 6.3. EHR Mining
  • 6.4. Intensified ADR Reporting
  • 6.5. Spontaneous Reporting
  • 6.6. Targeted Spontaneous Reporting

7. Pharmacovigilance Market, by Product Life Cycle

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV
  • 7.6. Pre-clinical

8. Pharmacovigilance Market, by Delivery Mode

  • 8.1. Introduction
  • 8.2. In-house
  • 8.3. Outsourced

9. Pharmacovigilance Market, by Process Flow

  • 9.1. Introduction
  • 9.2. Case Data Management
    • 9.2.1. Case Data Analysis
    • 9.2.2. Case Logging
    • 9.2.3. Medical Reviewing & Reporting
  • 9.3. Risk Management System
    • 9.3.1. Risk Evaluation System
    • 9.3.2. Risk Mitigation System
  • 9.4. Signal Detection
    • 9.4.1. Adverse Event Analysis
    • 9.4.2. Adverse Event Logging
    • 9.4.3. Adverse Event Review & Reporting

10. Pharmacovigilance Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Cardiovascular
  • 10.3. Infectious Diseases
  • 10.4. Neurology
  • 10.5. Oncology
  • 10.6. Respiratory

11. Pharmacovigilance Market, by End-user

  • 11.1. Introduction
  • 11.2. Biotechnology Companies
  • 11.3. Medical Device Manufacturers
  • 11.4. Pharmaceuticals

12. Americas Pharmacovigilance Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Pharmacovigilance Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Pharmacovigilance Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. ProductLife Group's acquisition of Callisto enhances regulatory services and pharmacovigilance in the UK and EU
    • 15.3.2. EVERSANA and Oracle collaborate to transform proactive pharmacovigilance with AI-driven innovations
    • 15.3.3. Kenya and Malawi develop a partnership to advance pharmacovigilance and increase drug safety in Africa
    • 15.3.4. Qinecsa Solutions expands administration in pharmacovigilance with strategic acquisition of Insife ApS
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accenture, PLC
  • 2. Bristol-Myers Squibb Company
  • 3. Capgemini SE
  • 4. ClinChoice
  • 5. F. Hoffmann-La Roche AG
  • 6. GlaxoSmithKline PLC
  • 7. HCL Technologies Limited
  • 8. ICON PLC
  • 9. Infosys Limited
  • 10. International Business Machines Corporation
  • 11. IQVIA Inc.
  • 12. ITclinical
  • 13. Laboratory Corporation of America Holdings
  • 14. Linical Co., Ltd.
  • 15. Novartis AG
  • 16. Oracle Corporation
  • 17. Parexel International
  • 18. Pfizer Inc.
  • 19. Quanticate International limited
  • 20. Sanofi S.A.
  • 21. Syneos Health
  • 22. TAKE Solutions Limited
  • 23. TATA Consultancy Services Limited
  • 24. Wipro Limited

LIST OF FIGURES

  • FIGURE 1. PHARMACOVIGILANCE MARKET MULTI-CURRENCY
  • FIGURE 2. PHARMACOVIGILANCE MARKET MULTI-LANGUAGE
  • FIGURE 3. PHARMACOVIGILANCE MARKET RESEARCH PROCESS
  • FIGURE 4. PHARMACOVIGILANCE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOVIGILANCE MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 192. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 201. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 210. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 211. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 219. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 220. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 238. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 239. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 247. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 248. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 256. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 257. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 265. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 266. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 274. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 275. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 283. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 284. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 292. ITALY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 293. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 301. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 302. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 310. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 311. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 319. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 320. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 328. POLAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 329. POLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 335. QATAR PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 336. QATAR PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 337. QATAR PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 338. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
  • TABLE 341. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
  • TABLE 342. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
  • TABLE 343. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 344. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 345. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
  • TABLE 346. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 347. RUSSIA PHARMACOVIGI